These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30595885)

  • 21. Clinico-Pathologic Profile and Treatment Outcomes of Patients with Diffuse Large B Cell Lymphoma Based on Cell of Origin Classification.
    Mandloi SS; Thumaty DB; Nisha Y; Kayal S; Ganesan P; Jacob SE; Basu D; Dubashi B
    Indian J Hematol Blood Transfus; 2021 Apr; 37(2):226-231. PubMed ID: 33867728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
    [No Abstract]   [Full Text] [Related]  

  • 24. Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Asrini R; Ham MF; Asmarinah A; Harahap AS; Hardjolukito ESR
    Mol Clin Oncol; 2022 Feb; 16(2):42. PubMed ID: 35003740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
    Akkas BE; Vural GU
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.
    Wu C; Wu X; Zhang X; Chai Y; Guo Q; Li L; Yue L; Bai J; Wang Z; Zhang L
    Int J Clin Exp Med; 2015; 8(9):15173-81. PubMed ID: 26629001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
    Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
    Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopathological Characteristics of Patients with Intestinal Diffuse Large B-Cell Lymphoma].
    Mou K; Shi ML; Yang FL; Wu XF; Guo XQ; Qi JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):508-514. PubMed ID: 33812422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD56-positive diffuse large B-cell lymphoma: comprehensive analysis of clinical, pathological, and molecular characteristics with literature review.
    Gasljevic G; Boltezar L; Novakovic S; Setrajcic-Dragos V; Jezersek-Novakovic B; Kloboves-Prevodnik V
    Radiol Oncol; 2023 Jun; 57(2):249-256. PubMed ID: 36942468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.
    Chen GL; Li D; Cao S; Jiang S; Zhang Q; Jin J; Xia Z; Liu Y; Liu X; Zhu Y; Chen Y; Gu L; Hong X; Cao J; Tao R; Lv F
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022066. PubMed ID: 36119461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.
    Qu Z; Zhang T; Gao F; Gong W; Cui Y; Qiu L; Qian Z; Zhou S; Meng B; Ren X; Li L; Wang X; Zhang H
    Biomed Res Int; 2022; 2022():4379556. PubMed ID: 35655476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
    Ye ZY; Cao YB; Lin TY; Lin HL
    Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Sun J; Zhu X; Zhao Y; Zhou Q; Qi R; Liu H
    Pharmgenomics Pers Med; 2021; 14():397-408. PubMed ID: 33833551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation.
    Hashmi AA; Iftikhar SN; Nargus G; Ahmed O; Asghar IA; Shirazi UA; Afzal A; Irfan M; Ali J
    Cureus; 2021 Feb; 13(2):e13155. PubMed ID: 33692924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
    Saad AA; Awed NM; Abdel-Hafeez ZM; Kamal GM; Elsallaly HM; Alloub AI
    Saudi Med J; 2010 Feb; 31(2):135-41. PubMed ID: 20174727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.